Drug treatment of lipid disorders

New England Journal of Medicine

Volumn 341, Issue 7, 1999, Pages 498-511

  Knopp, Robert H ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CYTOCHROME P450; DIGOXIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; STATIN; THIAZIDE DIURETIC AGENT; THYROXINE; WARFARIN;

ATHEROGENESIS; DIET RESTRICTION; DRUG ABSORPTION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERLIPIDEMIA; IMMUNOPATHOLOGY; LIPOPROTEIN BLOOD LEVEL; LIVER TOXICITY; NEUROTOXICITY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SKIN TOXICITY;

ANION EXCHANGE RESINS; ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; CLOFIBRATE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MALE; NIACIN; RISK FACTORS;

EID: 0033549840     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199908123410707     Document Type: Review

References (138)

1. Rosamond WD, Chambless LE, Folsom AR, et al. Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. N Engl J Mcd 1998;339:861-7.
2. Murray CJL, Lopez AD. Mortality by cause for eight regions of the world: Global Bureau of Disease Study. Lancet 1997;349:1269-76.
3. Mortality statistics. In: Center for Health Statistics. Washington State Heart Disease and Stroke Prevention Plan. Olympia: Washington State Department of Health, 1995:1.
4. White AA. Mapping and geographic display of data. Stat Med 1995;14: 697-9.
5. Levinc GN, Keaney JF Jr, Vita JA. Cholesterol reduction in cardiovascular disease: clinical benefits and possible mechanisms. N Engl J Med 1995;332:512-21.
6. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995;15:551-61.
7. Knopp RH, Zhu X-D, Bonet B. Effects of estrogens on lipoprotein metabolism and cardiovascular disease in women. Atherosclerosis 1994;110: Suppl:S83-S91.
8. Rapp JH, Lespine A, Hamilton RL, et al. Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque. Arterioscler Thromb 1994;14:1767-74.
9. Coresh J, Kwiterovich PO Jr, Small, dense low-density lipoprotein particles and coronary heart disease risk: a clear association with uncertain implications. JAMA 1996;276:914-5.
10. Oram JF, Yokoyama S. Apolipoprotein-mediated removal of cellular cholesterol and phospholipids. J Lipid Res 1996;37:2473-91.
11. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res 1995;36:211-28.
12. Knopp RH. The effects of oral contraceptives and postmenopausal estrogens on lipoprotein physiology and atherosclerosis. In: Halbe HW, Rekers H, eds. Oral contraception into the 1990s. Carnforth, England: Parthenon Publishing, 1989:31-45.
13. Chait A, Albers JJ, Brunzell JD. Very low density lipoprotein overproduction in genetic forms of hypertriglyceridaemia. Eur J Clin Invest 1980; 10:17-22.
14. Ginsberg HN. Is hypertriglyceridemia a risk factor for atherosclerotic cardiovascular disease? A simple question with a complicated answer. Ann Intern Mcd 1997;126:912-4.
15. Brunzell JD. Familial lipoprotein lipase deficiency and other causes of the chylomicronemia syndrome: In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic bases of inherited disease. 7th ed. Vol. 2. New York: McGraw-Hill, 1995:1913-32.
16. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988;240:622-30.
17. Hokanson JE, Austin MA, Zambon A, Brunzell JD. Plasma triglyceride and LDL heterogeneity in familial combined hyperlipidemia. Arterioscler Thromb 1993;13:427-34.
18. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky A. Hyperlipidemia in coronary heart disease: genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 1973;52:1544-68.
19. Ginsburg HN, Goldberg IJ. Disorders of lipoprotein metabolism. In: Fauci AS, Braunwald E, Isselbacher KJ, a al., eds. Harrison's principles of internal medicine. 14th ed. Vol. 2. New York: McGraw-Hill, 1998:2138-49.
20. Havel RJ, Rapaport E. Management of primary hyperlipidemia. N Engl J Med 1995;332:1491-S. [Erratum, N Engl J Med 1995;333:467.]
21. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA 1993;269:3015-23.
22. Maher VMG, Brown BG, Marcovina SM, Hillger LA, Zhao X-Q, Albers JJ. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA 1995;274:1771-4.
23. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998;338:1042-50.
24. Chambless LE, Fuchs FD, Linn S, et al. The association of cornea! arcus with coronary heart disease and cardiovascular disease mortality in the Lipid Research Clinics Mortality Follow-up Study. Am J Public Health 1990;80:1200-4.
25. Diaz MN, Frei B, Vita JA, Keaney JF Jr. Antioxidants and atherosclerotic heart disease. N Engl J Med 1997;337:408-16.
26. Bachmaier K, Neu N, de la Maza LM, Pal S, Hessel A, Penninger JM. Chlamydia infections and heart disease linked through antigenic mimicry. Science 1999;283:1335-9.
27. Stone NJ. Secondary causes of hyperlipidemia. Med Clin North Am 1994;78:117-41.
28. Brunzell JD, Bierman EL. Chylomicronemia syndrome: interaction of genetic and acquired hypertriglyceridemia. Med Clin North Am 1982;66: 455-68.
29. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and lowdose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997;336:153-62. [Erratum, N Engl J Med 1997;337:1859.]
30. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987;257:3233-40. [Erratum, JAMA 1987;259:2698.]
31. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high lev-els of apolipoprotein B. N Engl J Med 1990;323:1289-98.
32. American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care 1999;22:Suppl 1:S56-S59.
33. Haffner SM, Lento S, Rönnemaa T, Pyörala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.
34. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
35. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
36. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
37. Sacks FM, Moyé LA, Davis BR, et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation 1998;97:1446-52.
38. The West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998;97:1440-5.
39. Pedersen TR, Olssoti AG, Faergeman O, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998;97:1453-60.
40. Grundy SM. Statin trials and goals of cholesterol-lowering therapy. Circulation 1998;97:1436-9.
41. Lipid Metabolism Branch, Division of Heart and Vascular Diseases, National Heart, Lung, and Blood Institute. The Lipid Research Clinics population studies data book. Vol. 1. The Prevalence Study: aggregate distribution of lipids, lipoproteins and selected variables in 11 North American populations. Bethesda, Md.: National Institutes of Health, 1980:1-136.
42. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience): Prospective Cardiovascular Munster Study. Am J Cardiol 1992;70:733-7.
43. Stampfer MJ, Krauss RM, Ma J, et al. A prospective study of triglyc-eride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996;276:882-8.
44. Knopp RH, Walden CE, Retzlaff BM, et al. Long-term cholesterol-lowering effects of 4 fat-restricted diets in hypercholesterolemic and combined hyperlipidemic men: the Dietary Alternatives Study. JAMA 1997; 278:1509-15.
45. Walden CE, Retzlaff BM, Buck BL, McCann BS, Knopp RH. Lipoprotein lipid response to the National Cholesterol Education Program Step II diet by hypercholesterolemic and combined hyperlipidemic women and men. Arterioscler Thromb Vasc Biol 1997;17:375-82.
46. Denke MA. Cholesterol-lowering diets: a review of the evidence. Arch Intern Med 1995;155:17-26.
47. Labarthe DR. Dietary fiber: further epidemiological support for a high-intake dietary pattern. Circulation 1996;94:2696-8.
48. Retzlaff BM, Walden CE, McNeney WB, Buck BL, McCann BS, Knopp RH. Nutritional intake of women and men on the NCEP Step I and Step II diets. J Am Coll Nutr 1997;16:52-61.
49. de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999;99:779-85.
50. Davignon J, Montigny M, Dufour R. HMG-CoA reductase inhibitors: a look back and a look ahead. Can J Cardiol 1992;8:843-64.
51. Mabuchi H, Haba T, Tatami R, et al. Effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10 levels in patients with familial hypercholesterolemia. N Engl J Med 1981;305:478-82.
52. Mabuchi H, Sakai T, Sakai Y, et al. Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia: additive effects of compactin and cholestyramine. N Engl J Med 1983;308:609-13.
53. Bilheimer DW, Grundy SM, Brown MS, Goldstein JL. Mevinolin and colestipol stimulate receptor-mediated clearance of low-density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc Natl Acad Sci U S A 1983;80:4124-8.
54. Arad Y, Ramakrishnan R, Ginsberg HN. Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins. Metabolism 1992;41:487-93.
55. Byington RP, Jukema JW, Salonen JT, et al. Reduction in cardiovascular events during pravastatin therapy: pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation 1995;92: 2419-25.
56. The Pravastatin Multinational Study Group for Cardiac Risk Patients. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol per liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. Am J Cardiol 1993;72:1031-7.
57. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998;279:1615-22.
58. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57
59. Crouse JR III, Byington RP, Hoen HM, Furberg CD. Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med 1997;157: 1305-10.
60. Bucher HC, Griffith LE, Guyatt GH. Effect of HMGcoA reductase inhibitors on stroke: a meta-analysis of randomized, controlled trials. Ann Intern Med 1998;128:89-95.
61. Hsu I, Spinier SA, Johnson NE. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Ann Pharmacothcr 1995;29:743-59.
62. The Pravastatin Multicenter Study Group II. Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Arch Intern Med 1993;153:1321-9.
63. Physicians' desk reference. Montvale, N.J.: Medical Economics, 1999.
64. Bakker-Arkema RG, Davidson MH, Goldstein RJ, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 1996;275:128-33.
65. Davidson MH, Stein EA, Dujovne CA, et al. The efficacy and six-week tolerability of simvastatin 80 and 160 mg per day. Am J Cardiol 1997;79: 38-42.
66. Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet 1996;348:1079-82. [Erratum, Lancet 1997; 349:214.]
67. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998;279:1643-50.
68. McPherson R, Tsoukas C, Baines MG, et al. Effects of lovastatin on natural killer cell function and other immunological parameters in man. J Clin Immunol 1993;13:439-44.
69. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995;333:621-7.
70. Llorente-Cortés V, Martínez-González J, Badimon L. Esterified cholesterol accumulation induced by aggregated LDL uptake in human vascular smooth muscle cells is reduced by HMG-CoA reductase inhibitors. Arterioscler Thromb Vase Biol 1998;18:738-46.
71. Cignarella A, Brennhausen B, von Eckardstcin A, Assmann G, Cullen P. Differential effects of lovastatin on the trafficking of endogenous and lip oprotein-derived cholesterol in human monocyte-derived macrophages. Arterioscler Thromb Vasc Biol 1998;18:1322-9.
72. Colli S, Eligini S, Lalli M, Camera M, Paoletti R, Tremoli E. Vastatins inhibit tissue factor in cultured human macrophages: a novel mechanism of protection against athcrothrombosis. Arterioscler Thromb Vasc Biol 1997; 17:265-72.
73. Kaesemeyer WH, Caldwell RB, Huang J, CaldweU RW. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol 1999;33:234-41.
74. Jahn CE, Schaefer EJ, Taam LA, et al. Lipoprotein abnormalities in primary biliary cirrhosis: association with hepatic lipase inhibition as well as altered cholesterol esterification. Gastroenterology 1985;89:1266-78.
75. Travia D, Tosi F, Negri C, Faccini G, Moghetti P, Muggeo M. Sustained therapy with 3-hydroxy-3-methylglutaryl-cocnzyme-A reductase inhibitors does not impair steroidogcncsis by adrenals and gonads. J Clin Endocrinol Metab 1995;80:836-40.
76. Abramowicz M, editor. Choice of lipid-lowering drugs. Med Lett 1996;38:67-70.
77. Vgontzas AN, Kales A, Bixler EO, Manfredi RJL, Tyson KL. Effects of lovastatin and pravastatin on sleep efficiency and sleep stage. Clin Pharmacol Ther 1991;50:730-7.
78. Roth T, Richardson GR, Sullivan JP, Lee RM, Merlotti L, Roehrs T. Comparative effects of pravastatin and lovastatin on nighttime sleep and daytime performance. Clin Cardiol 1992;15:426-32.
79. Partinen M, Pihl S, Strandberg T, et al. Comparison of effects on sleep of lovastatin and pravastatin in hypercholesterolemia. Am I Cardiol 1994; 73:876-80.
80. deVries ACJ, Cohen LH. Different effects of the hypolipidemic drugs pravastatin and lovastatin on the cholesterol biosynthesis of the human ocular lens in organ culture and on the cholesterol content of the rat lens in vivo. Biochim Biophys Acta 1993;1167:63-9.
81. Laties AM, Keates EU, Taylor HR, et al. The human lens after 48 weeks of treatment with lovastatin. N Engl J Med 1990;323:683-4.
82. Bradford RH, Shear CL, Chremos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991;151:43-9.
83. Hanston PD, Horn JR. Drug interactions with HMG CoA reductase inhibitors. Drug Interactions Newsletter 1998:103-6. (Vancouver, Wa.: Applied Therapeutics.)
84. Illingworth DR, Tobert JA. A review of clinical trials comparing HMG-CoA reductase inhibitors. Clin Ther 1994;16:366-85.
85. Leitersdorf E, Muratti EN, Eliav O, et al. Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia: comparative analysis with a fluvastatin-cholcstyramine combination. Am J Med 1994;96:401-7.
86. Wiklund O, Angelin B, Bergman M, et al. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med 1993;94:13-20.
87. Feher MD, Foxton J, Banks D, Lant AF, Wray R. Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease. Br Heart J 1995;74: 14-7.
88. Smit JWA, Jansen GH, de Bruin TWA, Erkelens DW. Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damage. Am J Cardiol 1995;76: 126A-128A,
89. Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990; 264:71-5.
90. Arad Y, Ramakrishnan R, Ginsberg HN. Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipide-mia by reducing the production of apoB-coctaining lipoproteins: implications for the pathophysiology of apoB production. J Lipid Res 1990;31: 567-82.
91. Broyles FE, Walden CE, Hunninghake DB, Hill-Williams D, Knopp RH. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia. Am J Cardiol 1995; 72:129A-135A.
92. Knopp RH, Walden CE, Heiss G, Johnson JL, Wahl PW. Prevalence and clinical correlates of beta-migrating very-low-ensity lipoprotein: Lip-id Research Clinics Program Prevalence Study. Am J Med 1986;81:493-502.
93. Vega GL, East C, Grundy SM. Lovastatin therapy in familial dysbetalipoproteinemia: effects on kinetics of apolipoprotein B. Atherosclerosis 1988;70:131-43.
94. Knopp RH, Frohlich J, Jokubaitis LA, Dawson K, Broyles FE, Gomez-Coronado D. Efficacy and safety of fluvastatin in patients with non-insulin-dependent diabetes mellitus and hyperlipidemia. Am J Med 1994; 96:69S-78S.
95. Vega GL, Grundy SM. Lovastatin therapy in nephrotic hyperlipidemia: effects on lipoprotein metabolism. Kidney Int 1988;33:1160-8.
96. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-64.
97. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251:365-74.
98. Packard CJ, Shepherd J. The hepatobiliary axis and lipoprotein metabolism: effects of bile acid sequestrants and ileal bypass surgery. J Lipid Res 1982;23:1081-98.
99. Altschul R, Hoffer A, Stephen JD. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem Biophys 1955;54:558-9.
100. Knopp RH, Ginsberg J, Albers JJ, et al. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism 1985;34:642-50.
101. Grundy SM, Mok HYI, Zech L, Berman M. Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. J Lipid Res 1981;22:24-36.
102. Knopp RH, Alagona P, Davidson M, et al. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night vs. plain niacin in the management of hyperlipidemia. Metabolism 1998;47:1097-104.
103. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990;264:3007-12.
104. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988;223:405-18.
105. Clofibrate and niacin in coronary heart disease. JAMA 1975;231: 360-81.
106. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-55.
107. Davignon J, Roederer G, Montigny M, et al. Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia. Am J Cardiol 1994;73:339-45.
108. Stein EA, Davidson MH, Dujovne CA, et al. The efficacy and tolerability of low dose simvastatin and niacin, alone and in combination, in patients with combined hyperlipidemia: a prospective trial. J Cardiovasc Pharmacol Ther 1996;1:107-16.
109. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213-9.
110. McKenney JM, Proctor JD, Harris S, Chinchili VM. A comparison of the efficacy and toxic effects of sustained-vs. immediate-release niacin in hypercholesterolemic patients. JAMA 1994;271:672-7.
111. Illingworth DR, Stein EA, Mitchel YB, et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia: a prospective trial. Arch Intern Med 1994;154:1586-95.
112. Ide T, Oku H, Sugano M. Reciprocal responses to clofibrate in ketogenesis and triglyceride and cholesterol secretion in isolated rat liver. Metabolism 1982;31:1065-72.
113. Nikkilä EA, Huttunen JK, Ehnholm C. Effect of clofibrate on post-heparin plasma triglyceride lipase activities in patients with hypertriglyceridemia. Metabolism 1977;26:179-86.
114. Auwerx J, Schoonjans K, Fruchart J-C, Staels B. Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR. Atherosclerosis 1996;124:Suppl:S29-S37.
115. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart J-C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998;98:2088-93.
116. Knopp RH, Brown WV, Dujovne CA, etal. Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia. Am J Med 1987;83:50-9.
117. de Graaf J, Hendriks JC, Demacker PN, Stalenhoef AF. Identification of multiple dense LDL subfractions with enhanced susceptibility to in vitro oxidation among hypertriglyceridemic subjects: normalization after clofibrate treatment. Arterioscler Thromb 1993;13:712-9.
118. Jen S-L, Chcn J-W, Lee W-L, Wang S-P. Efficacy and safety of fenofibrate or gemfibrozil on serum lipid profiles in Chinese patients with type IIb hyperlipidemia: a single-blind, randomized, and cross-over study. Chung Hua I Hsueh Tsa Chin (Taipei) 1997;59:217-24.
119. Brown WV, Dujovne CA, Farquhar WJ, et al. Effects of fenofibrate on plasma lipids: double-blind, multicenter study in patients with type IIA or IIB hyperlipidemia. Arteriosclerosis 1986;6:670-8.
120. Knopp RH, Walden CE, Warnick GR, Albers JJ, Ginsberg J, McGinnis BM. Effect of fenofibrate treatment on plasma lipoprotein lipid, high-density lipoprotein cholesterol subfractions, and apolipoproteins B, AI, All, and E. Am J Med 1998;83:75-84.
121. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety in treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-45.
122. Rubins H. The Veterans Affairs HDL Intervention Trial (VA-HIT). Presented at plenary session XII of the 71st Annual Meeting of the American Heart Association, Dallas, November 11, 1998.
123. Ferguson JJ. Highlights of the 71st scientific sessions of the American Heart Association. Circulation 1999;99:2486-91.
124. Abramowicz M, editor. Choice of lipid-lowering drugs. Med Lett 1998;40:117-22.
125. The Committee of Principal Investigators. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 1978;40:1069-118.
126. Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996;347:849-53.
127. Frick MH, Syvanne M, Nieminen MS, et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Circulation 1997;96:2137-43.
128. Schonfeld G. The effects of fibrates on lipoprotein and hemostatic coronary risk factors. Atherosclerosis 1994;111:161-74.
129. The Coronary Drug Project Research Group. Gallbladder disease as a side effect of drugs influencing lipid metabolism: experience in the Coronary Drug Project. N Engl J Med 1977;296:1185-90.
130. Rimm EB, Ascherio A, Giovannucci E, Spiegelman D, Stampfer MJ, Willett WC. Vegetable, fruit, and cereal fiber intake and risk of coronary heart disease among men. JAMA 1996;275:447-51.
131. Truswell AS. Dietary fibre and plasma lipids. Eur J Clin Nutr 1995; 49:Suppl 3:S105-S109.
132. Miettinen TA, Puska P, Gylling H, Vanhanen H, Vartiainen E. Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. N Engl J Med 1995;333:1308-12.
133. Rambjor GS, Wålen Al, Windsor SL, Harris WS. Eicosapentaenoic acid is primarily responsible for hypotriglyceridemic effect of fish oil in humans. Lipids 1996;31:Suppl:S45-S49.
134. Knopp RH, Zhu X-D, Lau J, Walden CE. Sex hormones and lipid interactions: implications for cardiovascular disease in women. The Endocrinologist 1994;4:286-301.
135. Knopp RH. Estrogen, female gender, and heart disease. In: Topol E, ed. Textbook of cardiovascular medicine. Philadelphia: Lippincott-Raven, 1998:195-218.
136. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-13.
137. Albers JJ, Taggart HM, Applebaum-Bowden D, Haffner S, Chesnut CH III, Hazzard WR. Reduction of lecithin-cholesterol acyltransferase, apolipoprotein D and the Lp(a) lipoprotein with the anabolic steroid stanozolol. Biochim Biophys Acta 1984;795:293-6.
138. Mabuchi H, Koizumi J, Shimizu M, et al. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Am J Cardiol 1998;82:1489-95.